Kids are not mini adults. Child and adult cancers are biologically different, yet children are still treated with toxic therapies designed for adults.
Harsh chemotherapy, radiotherapy and surgery cause harm to children’s developing bodies and leave survivors with lifelong health challenges.
Kindling Bio put children first by developing targeted cancer gene therapy to harness the power of children’s immune system to fight a wide range of tumours.
Jeff is a serial biotechnology entrepreneur, having founded successful companies in stem cell storage, viral stabilisation and vaccine delivery. With a PhD in Molecular Virology, he continues to dedicate his career to improving child health.
Aleck brings over 17 years of cancer and child health research experience at leading UK research institutions. With a PhD in Cancer Cell Biology he is committed to driving change for some of society’s most vulnerable patients.
Head of Business Development and Venture Portfolio Pharma at Deep Science Ventures. Laura brings extensive experience in oncology deal-making, licences, and spin-outs. Formerly Associate Director of Cancer Research UK’s Commercial Partnerships.
